grant
Navigating Pathways of Innate Immunity and Epigenetic Memory in Checkpoint Immunotherapy
Organization BETH ISRAEL DEACONESS MEDICAL CENTERLocation BOSTON, UNITED STATESPosted 1 Aug 2025Deadline 31 Jul 2032
NIHUS FederalResearch GrantFY2025AblationAffectAmericanAntigensAntitumor ResponseAutologousB cell differentiation factorB cell stimulating factor 2B-Cell Differentiation FactorB-Cell Differentiation Factor-2B-Cell Stimulatory Factor-2BCDFBSF-2BSF2Basal Transcription FactorBasal transcription factor genesBlood Precursor CellBlood monocyteBone MarrowBone Marrow Reticuloendothelial SystemCRISPR editing screenCRISPR screenCRISPR-based screenCRISPR/Cas9 screenCancer PatientCancer TreatmentCancersCell DifferentiationCell Differentiation processCheckpoint inhibitorChemotactic CytokinesCuesDendritic CellsEmergenciesEmergency SituationEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessFutureGene ExpressionGeneral Transcription Factor GeneGeneral Transcription FactorsGenerationsGoalsHOX1.8HOX1HHOXA10HOXA10 geneHPGFHematopoietic Progenitor CellsHematopoietic stem cellsHepatocyte-Stimulating FactorHomeobox 1HHomeobox A10Homologous Chemotactic CytokinesHybridoma Growth FactorIFNIFN-beta 2IFNB2IL-6IL6 ProteinImmune checkpoint inhibitorImmune mediated therapyImmunityImmunobiologyImmunologically Directed TherapyImmunophysiologyImmunotherapyInnate ImmunityIntercrinesInterferonsInterleukin-6KnowledgeLaboratoriesLinkMGC12859MGI-2Malignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMarrow monocyteMediatingMediatorMiceMice MammalsMurineMusMyelogenousMyeloidMyeloid CellsMyeloid Differentiation-Inducing ProteinMyelopoiesisNative ImmunityNatural ImmunityNon-Specific ImmunityNonspecific ImmunityPD 1PD-1PD1Pathway interactionsPatientsPhagocytosisPhosphorylationPlasmacytoma Growth FactorProcessProtein PhosphorylationReceptor ProteinResearchResistanceRoleSIS cytokinesSightSystemT cell responseT-CellsT-LymphocyteTrainingTranscription Factor Proto-OncogeneTranscription factor genesTranslatingTumor ImmunityVeiled CellsVisionWorkadaptive immunityanti-cancer immunotherapyanti-cancer therapyanti-tumor immunityanti-tumor responseanticancer immunotherapyantigen-specific T cellsantitumor immunityblood cell progenitorblood progenitorblood stem cellblood-forming stem cellcancer immunitycancer immunotherapycancer therapycancer-directed therapycellular differentiationcheck point immunotherapycheck point inhibitor therapycheck point inhibitory therapycheck point therapycheckpoint immunotherapycheckpoint inhibitor therapycheckpoint inhibitory therapycheckpoint therapychemoattractant cytokinechemokineclustered regularly interspaced short palindromic repeats screenepigenetic memoryepigeneticallyhematopoietic progenitorhematopoietic stem progenitor cellhemopoietic progenitorhemopoietic stem cellimmune check pointimmune check point inhibitorimmune check point therapyimmune checkpointimmune checkpoint therapyimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based cancer therapiesimmune-based therapiesimmune-based treatmentsimmunecheckpointimmuno therapyimmunogenimmunotherapy for cancerimmunotherapy of cancerimprintinterferon beta 2malignancymonocyteneoplasm/cancernew approachesnext generationnovelnovel approachesnovel strategiesnovel strategypathwaypersonalized immunotherapyprecision immunotherapyprogenitor cell differentiationprogenitor differentiationprogrammed cell death 1programmed cell death protein 1programmed death 1programsreceptorrecruitresistantresponsesle2social rolestandard carestandard treatmentstem and progenitor differentiationstem cell differentiationsystemic lupus erythematosus susceptibility 2thymus derived lymphocytetranscription factortumorvisual function
Description preview
My laboratory has been at the vanguard of the discovery of costimulatory molecules and checkpoint inhibitors
and their role in cancer. The field of cancer immunotherapy has mainly focused on the impact of immune
checkpoints (IC) and their blockade on the activation of tumor-associated T cells. Although antigen recognition
is important, it is only…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click